New injection for high blood pressure enters first human tests

NCT ID NCT06823947

Recruiting now Disease control Sponsor: Kyowa Kirin Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called KK3910 in healthy people and those with high blood pressure. The main goal is to check safety and how the drug moves through the body. It is a small, placebo-controlled study, so it is too soon to know if the drug actually works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KK3910
What this could lead to: If successful, this could lead to a new injectable treatment option for high blood pressure.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. It is small and may not show enough benefit or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS ESSENTIAL HYPERTENSION

Contacts and locations

Locations

Kitasato University Kitasato Institute Hospital
RECRUITING

Minato-ku, Tokyo, 108-8642, Japan
Medical Corporation Heishinkai OPHAC Hospital
NOT_YET_RECRUITING

Yodogawa, Osaka, 532-0003, Japan
SOUSEIKAI PS Clinic
NOT_YET_RECRUITING

Hakata, Fukuoka, 812-0025, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.